Moreover, they further performed a sample stratification using Sparse Partial Least Squares Discriminant Analysis (sPLS-DA) and they proved that UCH-L1 levels measured not only in the CSF, but also in the plasma, were valid biomarkers for distinguishing between AD patients and controls, pointing to the relevance of this enzyme in the context of neurodegenerative disorders [105]. Here, UCHL1 is linked to Alzheimer disease.